Report Description Table of Contents Antithyroid Agents Market: How Are Hyperthyroidism Cases, Graves' Disease Treatment, and Methimazole Prescriptions Supporting Growth? – (Updated On: 19th-Nov-2026) According to Strategic Market Research, the Global Antithyroid Agents Market was valued at USD 395 million in 2025 and is projected to reach USD 500 million by 2032, growing at a CAGR of 3.42% during 2026–2032. Demand is supported by established treatment of Graves' disease, continuing methimazole and carbimazole prescriptions, and the growing clinical acceptance of prolonged antithyroid therapy in selected patients. Generic drug availability supports treatment access, while radioactive iodine, thyroid surgery, and emerging therapies influence long-term pharmaceutical demand. Hyperthyroidism represents an established treatment population, particularly among patients with Graves' disease. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Graves' disease affects nearly 1 in 100 Americans and accounts for approximately four out of five U.S. hyperthyroidism cases. Antithyroid medicines remain an important nonsurgical treatment option, particularly for patients who prefer medication or are not suitable for definitive procedures. The large underlying patient population supports recurring prescription demand, although actual medicine utilization depends on diagnosis, treatment selection, and disease severity. Recent clinical evidence demonstrates why Graves' disease can generate prolonged medication requirements. A study published in November 2026 in Archives of Endocrinology and Metabolism examined 425 adults treated with methimazole. Remission was achieved in 149 patients (35.1%), while 48 of those achieving remission (32.2%) subsequently relapsed. The mean treatment duration was 36.2 months, and median time to relapse was seven months. Although the study analyzed patients treated between 2002 and 2022, its recently published findings demonstrate how persistent disease and recurrence influence treatment duration and repeat prescriptions. International treatment preferences also favor pharmaceutical management of uncomplicated Graves' disease. An August 2026 review published in Frontiers in Endocrinology reported findings from a survey of 1,252 endocrinologists conducted in 2023, in which 91.5% preferred antithyroid drugs as initial treatment. This supports the established clinical position of medicines such as methimazole and carbimazole. However, physician preferences do not necessarily represent actual prescription volumes, and regional differences in the use of radioactive iodine and surgery remain important when assessing pharmaceutical revenue. Long-term methimazole treatment is receiving greater clinical attention as an alternative to definitive intervention in selected patients. An October 2026 review in Endocrine Practice reported that continuous methimazole treatment for at least 60 months was associated with relapse rates below 20%, compared with approximately 50% following conventional treatment courses in the studies reviewed. These findings support longer treatment periods for suitable patients, potentially sustaining pharmaceutical demand. However, extended treatment does not automatically increase revenue proportionately because generic medicines remain inexpensive and treatment decisions depend on individual clinical outcomes. Generic manufacturers remain central to market competition. AiPing Pharmaceutical's methimazole tablets were listed in the U.S. National Library of Medicine's DailyMed database with updated prescribing information on August 20, 2026. The listing identifies 5 mg and 10 mg tablets supplied under an abbreviated new drug application. This demonstrates current participation by generic suppliers in the U.S. market, where established pharmaceutical products compete primarily through pricing, availability, and prescription access rather than new therapeutic indications. Emerging treatments could eventually influence demand for conventional antithyroid medicines. In April 2026, Immunovant reported that its Phase III batoclimab studies in thyroid eye disease failed to meet their primary endpoints, while continuing development of IMVT-1402 for autoimmune conditions, including Graves' disease. These research programs represent potential future competition rather than approved replacements for methimazole or carbimazole. Commercial impact will depend on successful clinical outcomes, regulatory authorization, and the ability of new treatments to reduce dependence on conventional antithyroid medication. Overall, the Antithyroid Agents Market is supported by the continued use of established medicines across Graves' disease and other hyperthyroid conditions. Methimazole provides the largest modeled revenue contribution, while carbimazole and propylthiouracil serve additional patient requirements. Prolonged treatment, repeat prescribing, and access to affordable generic medicines support market demand, while serious adverse reactions, treatment discontinuation, and alternative therapies limit revenue expansion. Which Subsegments Lead the Global Antithyroid Agents Market and Which Are Emerging as the Fastest-Expanding Opportunities? By Drug Type: Methimazole Leads the Market While Alternative Antithyroid Medicines Serve Specialized Treatment Needs Leading Subsegment — Methimazole Methimazole dominates the Antithyroid Agents Market with an estimated 54% share, valued at USD 213.30 million in 2025, and is projected to grow at a CAGR of 3.74% during 2026–2032. Its market leadership reflects established use in Graves' disease, availability of affordable generics, and suitability for continued outpatient treatment. A January 2026 prospective study comparing long-term methimazole treatment with thyroidectomy followed 208 patients, with 104 in each treatment group. Patients receiving long-term methimazole spent 94.21% of follow-up time with normal thyroid function, compared with 82.67% among patients who underwent thyroidectomy and received thyroid hormone replacement. Fastest-Growing Subsegment — Other Antithyroid Agents Other Antithyroid Agents account for an estimated 5% market share, equivalent to USD 19.75 million in 2025 revenue, and are projected to record the fastest drug-type CAGR of 4.34% during 2026–2032. This smaller category covers qualifying alternatives used in specific hyperthyroidism treatment circumstances. Commercially available nonstandard formulations provide one example: the UK electronic Medicines Compendium lists a carbimazole 2.5 mg/mL oral solution from Rosemont Pharmaceuticals. Such products can serve patients requiring alternative administration or individualized dosing. However, differentiated presentations do not automatically constitute a separate drug class, and their revenue must not be counted twice. The category's modeled growth requires validation against actual marketed products and prescribing volumes. By Indication: Graves' Disease Accounts for Most Antithyroid Drug Revenue Leading and Fastest-Growing Subsegment — Graves’ Disease Graves' Disease accounts for the dominant 66% share of the Antithyroid Agents Market, representing USD 260.70 million in 2025 revenue, and is projected to register the fastest indication-level CAGR of 3.64% during 2026–2032. This indication generates substantial treatment demand because many patients begin pharmacological management before considering radioactive iodine or surgery. The 2026 review in Frontiers in Endocrinology identifies antithyroid medicines as an established treatment option while emphasizing the need for better therapies addressing the underlying autoimmune disease. Graves' disease remains the principal commercial indication, but current pharmaceutical revenue depends on patients actively receiving medication rather than the total number diagnosed. By Treatment Approach: Antithyroid Monotherapy Dominates While Combination Treatment Addresses Complex Cases Leading Subsegment — Antithyroid Drug Monotherapy Antithyroid Drug Monotherapy holds the largest estimated 73% share, equivalent to USD 288.35 million in 2025 revenue, and is projected to expand at a CAGR of 3.09% during 2026–2032. Methimazole and carbimazole remain established standalone treatment choices for many patients with uncomplicated hyperthyroidism. A 2026 American Thyroid Association review of long-term treatment safety highlighted antithyroid drugs, radioactive iodine, and thyroidectomy as the principal treatment alternatives, with selection influenced by clinical risks and patient preferences. Monotherapy maintains an established prescription base because it can be continued without immediate definitive intervention, although treatment discontinuation following remission limits indefinite utilization. Fastest-Growing Subsegment — Combination Therapy Combination Therapy represents an estimated 27% share, valued at USD 106.65 million in 2025, and is projected to register the fastest treatment-approach CAGR of 4.29% during 2026–2032. Combination treatment is relevant when antithyroid medicines are prescribed alongside beta-blockers or other supportive interventions. The August 2026 European Thyroid Association and British Thyroid Association consensus on thyroid emergencies confirms the importance of multiple medicines in thyroid storm management, including antithyroid therapy, cardiovascular symptom control, and corticosteroids. However, this is a specialized emergency application rather than evidence that combination treatment is increasing across routine Graves' disease care. By Route of Administration: Oral Medicines Dominate While Nonstandard Routes Remain Limited Leading Subsegment — Oral Administration Oral Administration dominates the Antithyroid Agents Market with an estimated 98% share, equivalent to USD 387.10 million in 2025 revenue, and is projected to grow at a CAGR of 3.37% during 2026–2032. Methimazole, carbimazole, and PTU are predominantly administered orally, making tablets central to outpatient hyperthyroidism treatment. The UK electronic Medicines Compendium's May 2026 product update identifies Aurobindo Pharma–Milpharm's 5 mg carbimazole tablets as a prescription antithyroid medicine. The availability of approved generic tablets from multiple manufacturers supports routine dispensing and treatment continuity, while established products face price competition. Fastest-Growing Subsegment — Other Routes of Administration Other Routes of Administration account for an estimated 2% market share, representing USD 7.90 million in 2025 revenue, and are projected to record the fastest CAGR of 6.02% during 2026–2032. Nonoral administration remains relevant mainly to severe illness or circumstances preventing standard oral dosing. Specialized treatment may involve rectal preparations, nasogastric administration, or intravenous methimazole in countries where such products are available. These are limited clinical applications rather than a broad commercial alternative to oral tablets. By Patient Group: Adults Lead Revenue While Pediatric Treatment Requires Specialized Prescribing Leading Subsegment — Adults Adults account for the largest 72% share of the Antithyroid Agents Market, equivalent to USD 284.40 million in 2025 revenue, and are projected to expand at a CAGR of 3.25% during 2026–2032. Adult demand is concentrated among patients with Graves' disease and toxic nodular hyperthyroidism. Treatment requirements depend on whether medication is selected for initial control, long-term management, or preparation for definitive intervention. Fastest-Growing Subsegment — Pediatric Patients Pediatric Patients account for an estimated 9% share, representing USD 35.55 million in 2025 revenue, and are projected to register the fastest patient-group CAGR of 4.15% during 2026–2032. An August 2026 study of 128 children with Graves' disease reported a shift toward methimazole-based treatment and declining use of radioactive iodine. Across the study's observation periods, radioactive iodine use decreased from 55.6% in 1999–2004 to 9.8% in 2020–2024, while methimazole became the exclusive initial antithyroid medicine. The results support the role of medication in pediatric treatment. By Distribution Channel: Retail Pharmacies Lead While Online Dispensing Represents a Developing Opportunity Leading Subsegment — Retail Pharmacies Retail Pharmacies account for the dominant 64% share of the Antithyroid Agents Market, representing USD 252.80 million in 2025 revenue, and are projected to grow at a CAGR of 2.90% during 2026–2032. Their leading position reflects the outpatient nature of treatment and the availability of established generic medicines. Repeat dispensing, accessible community pharmacies, and treatment affordability support this channel. Fastest-Growing Subsegment — Online Pharmacies Online Pharmacies account for an estimated 11% market share, equivalent to USD 43.45 million in 2025 revenue, and are projected to register the fastest distribution-channel CAGR of 6.60% during 2026–2032. Online prescription services may support patients requiring regular refills, particularly where electronic prescribing and regulated medicine delivery are established. The commercial opportunity lies in improved continuity of dispensing rather than increased medicine consumption per patient. By End User: Endocrinology Clinics Lead While Outpatient Healthcare Settings Support Continuing Treatment Leading Subsegment — Endocrinology Clinics Endocrinology Clinics hold the largest estimated end-user share at 43%, representing USD 169.85 million in 2025 revenue, and are projected to expand at a CAGR of 3.60% during 2026–2032. Their commercial role reflects responsibility for selecting antithyroid therapy, adjusting treatment, and evaluating patients with recurrent or persistent disease. The Endocrine Society's 2026 clinical review of Graves' disease treatment highlights the importance of remission assessment and individualized decisions between prolonged medication and definitive intervention. Specialist care can support treatment continuity, but clinical appointments and monitoring services should not be counted as pharmaceutical revenue. Fastest-Growing Subsegment — Other Healthcare Settings Other Healthcare Settings account for an estimated 16% share, equivalent to USD 63.20 million in 2025 revenue, and are projected to register the fastest end-user CAGR of 3.65% during 2026–2032. Primary care practices and other outpatient facilities can support prescription renewals, thyroid function monitoring, and referrals for patients requiring specialist evaluation. Their role is particularly important when patients receive stable treatment over prolonged periods. Country-Level Market Analysis: Where Are Antithyroid Prescriptions and Graves' Disease Treatment Creating Commercial Opportunities? United States — Largest Country Market and Established Generic Methimazole Supply The United States accounts for approximately 25% of global Antithyroid Agents Market revenue, equivalent to USD 98.75 million in 2025, making it the largest national market in the supplied estimates. The country is projected to expand at a CAGR of 2.80% during 2026–2032. The U.S. market is supported by methimazole prescribing for eligible Graves' disease and toxic multinodular goiter patients. A September 2026 update to the National Library of Medicine's StatPearls clinical reference identifies methimazole as the preferred initial oral treatment for most patients requiring antithyroid medication. Its established position supports outpatient prescription demand, while safety monitoring and alternative definitive therapies influence continued use. Supplier competition is also important in the United States. The FDA's September 2026 Approved Drug Product List identifies Rising Pharma Holdings among companies with approved methimazole products. Such generic participation supports medicine availability and purchasing options for pharmacies. However, the presence of approved competitors also limits opportunities for significant price increases in this mature drug category. India — Fastest-Growing Country Market and Established Carbimazole Treatment India accounts for an estimated 8% share of the Global Antithyroid Agents Market, valued at USD 31.60 million in 2025, and is projected to register the fastest country-level CAGR of 6.20% during 2026–2032. India's treatment opportunity is supported by a documented hyperthyroidism patient population and established prescribing of carbimazole. The Indian Thyroid Society's consensus statement, published in the January–April 2026 issue of Thyroid Research and Practice, reported hyperthyroidism prevalence of approximately 0.9%–1.5% in Indian community-based studies. The guidance identifies antithyroid medicines as a first-line treatment for Graves' disease and recognizes prolonged low-dose therapy in suitable patients. These recommendations support recurring drug requirements, although prevalence figures should not be interpreted as the number of patients actively receiving treatment. Domestic and multinational pharmaceutical companies contribute to India's antithyroid medicine supply. Abbott India's official product portfolio identifies Neo-Mercazole and Thyrocab as carbimazole brands available in 5 mg, 10 mg, and 20 mg strengths. Their established commercial presence illustrates the role of branded generic products in the country's thyroid treatment market. Revenue opportunities remain connected to affordable prescription supply, outpatient treatment access, and continuity of medication rather than premium-priced product launches. South Korea — Medication-Oriented Graves' Disease Management and Long-Term Treatment Demand South Korea represents an established pharmaceutical treatment market for Graves' disease, where antithyroid drugs are commonly selected before definitive intervention. Treatment patterns are influenced by national clinical preferences, the availability of endocrinology services, and patient willingness to continue medication after initial disease control. A June 2026 study abstract published in Value in Health examined major comorbidities following Graves' disease diagnosis using South Korea's Health Insurance Review and Assessment Service database. The research covered records from January 2018 through June 2024, demonstrating continuing use of national healthcare data to assess the clinical burden associated with Graves' disease. Although the study does not provide current antithyroid pharmaceutical sales, it supports the importance of monitoring treatment-related healthcare requirements. Commercial demand remains dependent on the number of patients choosing medication, continuing prescriptions, and requiring further treatment after recurrence. United Kingdom — Carbimazole Product Availability and Established Generic Competition The United Kingdom represents an established European antithyroid medicine market, particularly for carbimazole used in Graves' disease and other qualifying hyperthyroid conditions. The market includes several suppliers offering different tablet strengths, while NHS purchasing and prescribing arrangements influence generic medicine competition. The NHS-linked OpenPrescribing database's August 2026 dictionary release identifies multiple carbimazole 5 mg suppliers, including Glenmark Pharmaceuticals Europe, Morningside Healthcare, Flamingo Pharma, and Milpharm. The presence of several listed suppliers demonstrates the competitive structure of the UK's generic carbimazole market. However, supplier listings do not independently establish market shares or dispensing volumes. Commercial performance depends on actual prescriptions, product availability, and NHS reimbursement arrangements. What Are the Key Clinical and Therapeutic Applications of Antithyroid Agents? 1. Graves' Disease Management Graves' disease is the principal application of antithyroid medicines, with methimazole and carbimazole commonly prescribed when pharmacological treatment is selected. Patients may receive an initial treatment course followed by assessment of remission, or prolonged low-dose therapy when appropriate. Treatment outcomes determine whether patients continue medication, stop treatment, or move to radioactive iodine or surgery. The commercial opportunity is therefore associated with active treatment duration and subsequent prescription requirements rather than the total diagnosed Graves' disease population. 2. Toxic Multinodular Goiter and Toxic Adenoma Antithyroid medicines are used to control hyperthyroidism associated with toxic multinodular goiter and autonomously functioning thyroid nodules. Treatment is particularly relevant when patients require stabilization before radioactive iodine or surgery, or when definitive treatment is unsuitable. In the latter group, continuing low-dose medication may generate recurring prescriptions. Unlike Graves' disease, autonomous nodular hyperthyroidism generally does not achieve lasting remission from a conventional antithyroid treatment course, making long-term therapy a distinct pharmaceutical application. 3. Preoperative Thyroidectomy Preparation Antithyroid medicines are used before thyroidectomy to stabilize patients and reduce risks associated with uncontrolled hyperthyroidism. A 2026 surgical review of adult Graves' disease confirmed that preoperative treatment generally aims to restore normal thyroid function before surgery, with additional medicines such as potassium iodide considered in selected circumstances. This application generates short-term specialist and hospital prescription demand. However, successful thyroidectomy usually ends the requirement for antithyroid medication, limiting its long-term pharmaceutical revenue contribution. 4. Adjunctive Radioactive Iodine Therapy Antithyroid medicines may be used before or around radioactive iodine treatment to manage severe hyperthyroidism and reduce selected treatment-related risks. A systematic review and meta-analysis published in the March 2026 issue of The Journal of Clinical Endocrinology & Metabolism evaluated 21 randomized trials involving 1,914 participants. It found no significant overall improvement in radioactive iodine treatment success from adjunctive antithyroid medicines, although some thyroid-function outcomes differed between approaches. These findings support individualized treatment decisions rather than routine combination use in every patient. Commercial demand from this indication remains linked to selected short-term prescriptions. How Are Safety Monitoring, Alternative Treatments, and Emerging Therapies Influencing the Antithyroid Agents Market? Methimazole Safety — Continued Monitoring and Treatment Selection Antithyroid medicine safety is a significant commercial consideration because serious adverse reactions can lead to treatment discontinuation. A September 2026 study published in Thyroid evaluated 432 Chinese pediatric Graves' disease patients receiving methimazole. During follow-up, 104 patients (24.1%) experienced neutropenia, with most cases developing during the early treatment period. Among affected patients, the majority had mild neutropenia, while 2.8% developed severe neutropenia. These findings emphasize the importance of clinical monitoring in selected populations and demonstrate why treatment tolerability can influence prescription continuity. The results should not be generalized to all adult patients receiving methimazole. Propylthiouracil Safety — Restricted Use and Specialized Prescribing PTU remains important for selected patients but faces significant safety restrictions. The U.S. DailyMed labeling updated in August 2026 for Par Health USA's propylthiouracil tablets includes a boxed warning for severe liver injury and acute liver failure. The labeling reserves PTU for patients who cannot tolerate methimazole when radioactive iodine or surgery is unsuitable, with additional considerations for early pregnancy. These restrictions limit PTU's commercial use compared with methimazole, while preserving demand in specific clinical situations. Radioactive Iodine and Surgery — Competition With Long-Term Pharmaceutical Treatment Radioactive iodine and thyroidectomy remain alternatives to continuing antithyroid therapy. Their commercial significance is greatest among patients with recurrent hyperthyroidism, inadequate medicine response, or adverse reactions. Successful definitive treatment can reduce future antithyroid prescriptions, even when patients subsequently require thyroid hormone replacement. Consequently, greater use of definitive procedures may affect antithyroid drug treatment volumes without necessarily reducing the overall need for thyroid-related healthcare. Emerging Graves' Disease Treatments — Potential Future Market Differentiation Development of autoimmune-directed medicines could eventually change Graves' disease treatment. Japan's clinical trial registry recorded a 2026 study of IMVT-1402 involving adults with Graves' disease, with outcomes assessing the proportion of patients achieving normal thyroid function without continuing antithyroid medication. The program demonstrates interest in treatments that could reduce dependence on conventional drugs. However, it remains investigational, and clinical trial registration does not establish efficacy, regulatory approval, or commercial revenue. Competitive Landscape and Leading Antithyroid Drug Manufacturers: How Are Branded Medicines, Generic Suppliers, and Treatment Availability Shaping Competition? Pfizer Inc. maintains a documented presence in the Antithyroid Agents Market through Tapazole (methimazole), an established prescription treatment for hyperthyroidism. Pfizer's official product labeling identifies Tapazole in 5 mg and 10 mg tablet strengths for eligible patients with Graves' disease or toxic multinodular goiter, as well as preparation for thyroidectomy or radioactive iodine therapy. The product illustrates the continuing relevance of established branded antithyroid medicines. However, current Tapazole-specific revenue and Pfizer's market share were not verified, so its commercial position should not be described as global market leadership. Macleods Pharmaceuticals participates directly in the generic antithyroid market through propylthiouracil tablets. The FDA's September 2026 Approved Drug Product List identifies Macleods Pharmaceuticals as an applicant associated with propylthiouracil. The company's participation provides an example of generic pharmaceutical competition in a specialized antithyroid drug category. Commercial demand for PTU remains smaller than methimazole because of its restricted clinical role and significant safety precautions. ADVANZ Pharma participates in the United Kingdom's carbimazole treatment market through prescription tablet products. The UK electronic Medicines Compendium lists ADVANZ Pharma among the suppliers of carbimazole 20 mg tablets. Its presence contributes to the availability of established antithyroid formulations in the European pharmaceutical market. Competition is influenced by product registrations, NHS purchasing conditions, and the availability of generic alternatives rather than major differences in therapeutic indications. Flamingo Pharma (UK) Limited supplies carbimazole formulations across several strengths. The company's product information identifies 5 mg, 10 mg, 15 mg, and 20 mg presentations, providing alternatives for clinicians prescribing different treatment doses. The availability of multiple strengths supports pharmacy access and individualized treatment, although it does not independently establish prescription volumes or manufacturer market share. Commercial opportunities remain associated with generic supply and participation in established antithyroid medicine purchasing arrangements. Rosemont Pharmaceuticals participates in a specialized formulation category through carbimazole oral solution. This formulation provides a commercially documented alternative for patients who require liquid medicine or individualized dosing. Its relevance is narrower than conventional tablet products, but it illustrates how manufacturers can differentiate within an established therapy area without introducing a new active pharmaceutical ingredient. Revenue potential remains dependent on prescription eligibility, product availability, and demand for alternative formulations. Research Methodology: How Are Hyperthyroidism Cases, Antithyroid Prescriptions, and Pharmaceutical Sales Assessed? The Global Antithyroid Agents Market assessment focuses on pharmaceutical medicines used to manage Graves' disease and other qualifying conditions associated with excessive thyroid hormone production. The core market includes methimazole, carbimazole, propylthiouracil, and other qualifying antithyroid agents. Radioactive iodine procedures, thyroidectomy, thyroid hormone replacement medicines, and unrelated supportive therapies are excluded unless explicitly identified within a broader market definition. Market estimates are assessed using disease prevalence, treatment eligibility, clinical prescribing patterns, pharmaceutical product availability, and relevant manufacturer disclosures. Hyperthyroidism prevalence establishes the underlying patient population, while prescription utilization, treatment duration, relapse, and patient adherence provide more direct indicators of drug demand. Clinical studies and treatment guidelines are used to establish the relevance of specific therapeutic applications, but they do not independently determine pharmaceutical revenue. The market is evaluated across drug type, indication, treatment approach, route of administration, patient group, distribution channel, end user, and geography. These categories provide different classifications of the same market. Their revenues must not be added across segmentation groups, and medicines prescribed alongside antithyroid drugs should be excluded unless the market scope explicitly includes them. The research considers generic pricing, pharmacy distribution, regulatory approvals, medicine safety, and competition from definitive hyperthyroidism treatments. Manufacturer participation is assessed using documented pharmaceutical products and official regulatory records. Companies without verified antithyroid medicines are distinguished from suppliers with identifiable commercial products. The historical period is 2019–2024, the base year is 2025, and the forecast period is 2026–2032. The global market valuation, segment shares, country-level revenue estimates, and forecast CAGRs represent provisional Strategic Market Research estimates. The clinical and regulatory evidence supports the market's treatment scope, but the supplied revenue estimates require further reconciliation with manufacturer sales and prescription data before independent validation. Analyst Commentary: How Will Generic Competition, Long-Term Treatment, and Emerging Therapies Shape the Antithyroid Agents Market? The Antithyroid Agents Market is supported by established treatment demand for Graves' disease and other hyperthyroid conditions. Methimazole remains the largest modeled drug category, while carbimazole and PTU serve additional treatment requirements. Growing clinical acceptance of prolonged antithyroid treatment may support recurring prescriptions among selected patients, although low generic prices limit revenue expansion. Competition from radioactive iodine, thyroid surgery, and emerging autoimmune-directed therapies will continue to influence treatment selection. Manufacturers with reliable generic supply, established pharmacy access, and differentiated formulations are positioned to compete in this mature pharmaceutical market. Antithyroid Agents Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 395 Million Revenue Forecast in 2032 USD 500 Million Overall Growth Rate CAGR of 3.42% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Drug Type, By Indication, By Treatment Approach, By Route of Administration, By Patient Group, By Distribution Channel, By End User, By Geography By Drug Type Methimazole, Carbimazole, Propylthiouracil (PTU), Other Antithyroid Agents By Indication Graves’ Disease, Toxic Multinodular Goiter, Toxic Adenoma, Other Hyperthyroid Conditions By Treatment Approach Antithyroid Drug Monotherapy, Combination Therapy By Route of Administration Oral Administration, Other Routes of Administration By Patient Group Adults, Pediatric Patients, Geriatric Patients By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies By End User Hospitals, Endocrinology Clinics, Other Healthcare Settings By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Established Graves’ disease treatment, recurring methimazole and carbimazole prescriptions, prolonged antithyroid therapy in selected patients, generic medicine availability supporting treatment access Customization Option Available upon request Frequently Asked Question About This Report Q1. What is driving demand for antithyroid medicines in the market? A1. The high prevalence of Graves' disease and the need for prolonged medication are supporting demand. Graves' disease affects nearly 1 in 100 Americans and accounts for approximately 80% of U.S. hyperthyroidism cases. Continued methimazole and carbimazole prescriptions provide a recurring pharmaceutical revenue base. Q2. How are long-term treatment patterns influencing the industry? A2. Longer methimazole treatment is gaining clinical attention as an alternative to definitive procedures in selected patients. An October 2026 review reported relapse rates below 20% following at least 60 months of continuous treatment, compared with approximately 50% after conventional treatment courses. This supports continued medication use among suitable patients. Q3. Which distribution channel offers the strongest growth opportunity in the market? A3. Online pharmacies are projected to record the fastest distribution-channel growth at a CAGR of 6.6% through 2032. Their expansion is supported by electronic prescriptions and convenient refills for patients requiring regular thyroid medication. Retail pharmacies will continue to lead because of established outpatient dispensing. Q4. What safety concerns are affecting prescribing practices in the industry? A4. Methimazole-related neutropenia and PTU-associated liver injury remain important treatment considerations. A 2026 study involving 432 Chinese pediatric patients reported neutropenia in 24.1% of those receiving methimazole. PTU also carries an FDA boxed warning for severe liver injury, restricting its use to selected clinical situations. Q5. Which regional markets are expected to experience stronger growth? A5. Asia-Pacific is projected to record the fastest regional CAGR of 4.76% through 2032. India is expected to grow fastest among the major country markets at 6.2%, supported by established carbimazole brands, improving thyroid disease management, and expanding access to affordable generic medicines. Q6. What emerging treatments could influence the future of the industry? A6. Autoimmune-directed therapies are being investigated as potential alternatives to conventional antithyroid treatment. Immunovant is developing IMVT-1402 for Graves' disease, with clinical studies assessing whether treatment can restore normal thyroid function without continued antithyroid medication. The candidate remains investigational and requires further clinical validation and regulatory approval. Sources: U.S. National Library of Medicine – AiPing Pharmaceutical’s Methimazole Label Updated August 20, 2026, Lists 5 mg and 10 mg Tablets Under an Abbreviated New Drug Application DailyMed – AiPing Methimazole: Generic Product Strengths and Hyperthyroidism Indications U.S. National Library of Medicine – Par Health’s Propylthiouracil Label Updated August 25, 2026, Retains a Boxed Warning for Severe Liver Injury and Acute Liver Failure, Supporting Its Restricted Treatment Role DailyMed – Propylthiouracil: Safety Restrictions, Methimazole Intolerance, and Early-Pregnancy Considerations U.S. FDA – September 2026 Approved Drug Product List Identifies Macleods Pharmaceuticals as an Applicant for Propylthiouracil, Confirming Its Documented Participation in the Generic Antithyroid Category FDA – September 2026 Approved Drug Product List: Propylthiouracil and Manufacturer Records Rosemont Pharmaceuticals – August 2025 Prescribing Information Documents Carbimazole 2.5 mg/mL Oral Solution for Hyperthyroidism, Thyroidectomy Preparation, and Treatment Around Radioactive Iodine Therapy Rosemont – Carbimazole Oral Solution: Official Product and Prescribing Information Immunovant – Reported on April 2, 2026, That Both Phase III Batoclimab Thyroid Eye Disease Studies Missed Their Primary Endpoint While Prioritizing IMVT-1402 Development, Including Graves’ Disease Immunovant – Batoclimab Phase III Results and Investigational Treatment Strategy Japan’s National Institute of Public Health – April 2026 Trial Registration Lists an IMVT-1402 Graves’ Disease Study Measuring Normal Thyroid Function Without Antithyroid Drugs at Week 26 NIPH Clinical Trials Search – IMVT-1402 in Adults With Graves’ Disease: jRCT2031260059 Immunovant – November 9, 2026, Corporate Update Expects Graves’ Disease IMVT-1402 Trial Results in 2027, Providing a Recent Development Timeline for Potential Future Competition Immunovant – November 2026 Corporate Update: Graves’ Disease Clinical Development Outlook Table of Contents – Global Antithyroid Agents Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, and End User Investment Opportunities in the Antithyroid Agents Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Methimazole, Carbimazole, Propylthiouracil, Generic Antithyroid Medicines, and Alternative Formulations Opportunities in Long-Term Graves' Disease Management, Pediatric Treatment, and Online Pharmacy Distribution Emerging Opportunities in Autoimmune-Directed Therapies for Graves' Disease Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Antithyroid Agents in Graves' Disease, Toxic Multinodular Goiter, Toxic Adenoma, and Other Hyperthyroid Conditions Role of Methimazole, Carbimazole, and Propylthiouracil in Pharmacological Hyperthyroidism Management Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Assessment of Disease Prevalence, Treatment Eligibility, Prescription Utilization, and Pharmaceutical Pricing Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Clinical Safety Factors Role of Established Graves' Disease Treatment and Long-Term Antithyroid Therapy in Market Expansion Generic Medicine Availability, Prescription Continuity, and Treatment Affordability Trends Impact of Radioactive Iodine, Thyroidectomy, and Emerging Autoimmune-Directed Therapies on Antithyroid Drug Demand Methimazole and Propylthiouracil Safety Monitoring and Treatment Discontinuation Trends Global Antithyroid Agents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Type: Methimazole Carbimazole Propylthiouracil (PTU) Other Antithyroid Agents Market Analysis by Indication: Graves' Disease Toxic Multinodular Goiter Toxic Adenoma Other Hyperthyroid Conditions Market Analysis by Treatment Approach: Antithyroid Drug Monotherapy Combination Therapy Market Analysis by Route of Administration: Oral Administration Other Routes of Administration Market Analysis by Patient Group: Adults Pediatric Patients Geriatric Patients Market Analysis by Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Market Analysis by End User: Hospitals Endocrinology Clinics Other Healthcare Settings Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Antithyroid Agents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, and End User Country-Level Breakdown: United States Canada Europe Antithyroid Agents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, and End User Country-Level Breakdown: United Kingdom Germany France Italy Rest of Europe Asia Pacific Antithyroid Agents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, and End User Country-Level Breakdown: China India Japan South Korea Rest of Asia-Pacific Latin America Antithyroid Agents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Antithyroid Agents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Pfizer Inc. Macleods Pharmaceuticals ADVANZ Pharma Flamingo Pharma (UK) Limited Rosemont Pharmaceuticals AiPing Pharmaceutical Abbott Laboratories Rising Pharma Holdings Aurobindo Pharma Sun Pharmaceutical Industries Teva Pharmaceutical Industries Viatris Inc. Hikma Pharmaceuticals Competitive Landscape and Strategic Insights Benchmarking Based on Antithyroid Drug Portfolios, Generic Product Availability, Formulation Range, Regulatory Approvals, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis Methimazole and Carbimazole Product Positioning Propylthiouracil Portfolio and Specialized Prescribing Analysis Generic Tablet and Alternative Formulation Strategy Analysis Long-Term Graves' Disease Treatment and Emerging Therapy Competition Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Guidelines, Product Labeling, and Regulatory Information Reviewed Through 2026 List of Tables Market Size by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, End User, and Region (2026–2032) Historical Market Size and Volume Analysis (2019–2024) Base Year Market Size Analysis (2025) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Antithyroid Agents Market Analysis Competitive Benchmarking of Leading Antithyroid Drug Manufacturers Generic Antithyroid Medicine and Formulation Availability Clinical Safety, Treatment Duration, and Prescription Utilization Analysis List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Drug Type, Indication, Treatment Approach, Route of Administration, Patient Group, Distribution Channel, and End User (2025 vs. 2032) Global Antithyroid Agents Ecosystem and Pharmaceutical Value Chain Analysis Graves' Disease Treatment Pathways and Antithyroid Drug Utilization